FRANKFURT, Germany, January 30, 2012 /PRNewswire/ --

A new premium version of Reaxys® for research intensive institutions

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of Reaxys Xcelerate™, a premium version of Reaxys® developed in close consultation with research intensive organizations.   Reaxys Xcelerate™ further extends the capabilities of Reaxys®, a leading workflow solution that provides extensive information on chemical compounds and reactions.

Reaxys Xcelerate™ has been designed to streamline research intensive chemistry workflows for:

• Synthetic chemists who need to view and analyze numerous potential retrosynthetic pathways can get immediate, automated, multiple synthetic plans, complete with access to the necessary background data, ensuring they can make informed decisions about the most effective routes to take to the lab.
  
• Chemistry researchers who need to compare and contrast multiple datasets can utilize Reaxys Xcelerate's intelligent results visualization, reducing data analysis complexity. Context sensitive graphical overviews and the ability to cluster results for maximum relevance enables immediate insights, which speeds up the analysis process.
  
• Global teams and diverse research groups who need to share information across labs and geographies can use enhanced information exchange capabilities. Researchers can pinpoint the exact area of interest, annotate with further insights or instructions and share instantly with colleagues for more effective teamwork.

"Working closely with our partners, we identified and invested in a number of new tools to support research intensive workflows," said Mark van Mierle, Managing Director of Elsevier's Pharma and Biotech Group.  "For organizations in competitive research environments, whether at corporations developing new materials, pharmaceutical organizations developing potential drugs, or academic institutions conducting groundbreaking research Reaxys Xcelerate™ provides a step change in individual and organizational productivity."

Reaxys ® and Reaxys Xcelerate™ follow the same agile development process, ensuring that the two versions continue to deliver the relevant content and insights needed by research chemists. To find out more about Reaxys Xcelerate™, including the opportunity to experience the product, visit http://www.reaxys.com/info/xcelerate.

Reaxys ® and the Reaxys trademark are owned and protected by Elsevier Properties SA and used under license.

 

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Tom Reller
Vice President, Global Corporate Relations, Elsevier
+1-215-239-3508
t.reller@elsevier.com

SOURCE Elsevier